These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 1903668)
1. Deprenyl: protective vs. symptomatic effect. Kofman OS Can J Neurol Sci; 1991 Feb; 18(1):83-5. PubMed ID: 1903668 [No Abstract] [Full Text] [Related]
2. R-(-)-deprenyl as a possible protective agent in Parkinson's disease. Tetrud JW; Langston JW J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606 [TBL] [Abstract][Full Text] [Related]
3. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Tetrud JW; Langston JW Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843 [TBL] [Abstract][Full Text] [Related]
4. Selegiline and the prophylaxis of Parkinson's disease. Sandler M; Willoughby J; Glover V; Gibb C J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604 [TBL] [Abstract][Full Text] [Related]
5. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease? Sandler M J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254 [TBL] [Abstract][Full Text] [Related]
6. Interactions among deprenyl, clorgyline and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on catecholamines in mice. Lee EH; Yang YL; Chia LG; Kuo JS Neurosci Lett; 1994 Jan; 165(1-2):149-52. PubMed ID: 7912414 [TBL] [Abstract][Full Text] [Related]
7. Big first scored with nerve diseases. Lewin R Science; 1989 Aug; 245(4917):467-8. PubMed ID: 2502841 [No Abstract] [Full Text] [Related]
8. Deprenyl: the exciting possibility of protective effect. Grimes JD Can J Neurol Sci; 1991 Feb; 18(1):85-6. PubMed ID: 1903669 [No Abstract] [Full Text] [Related]
9. Clinical trial for Parkinson's disease? Lewin R Science; 1985 Nov; 230(4725):527-8. PubMed ID: 3931220 [No Abstract] [Full Text] [Related]
10. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Cohen G; Pasik P; Cohen B; Leist A; Mytilineou C; Yahr MD Eur J Pharmacol; 1984 Oct; 106(1):209-10. PubMed ID: 6442232 [No Abstract] [Full Text] [Related]
11. Protective effect or symptomatic effect of deprenyl? Kofman OS N Engl J Med; 1993 Jun; 328(23):1715. PubMed ID: 8487839 [No Abstract] [Full Text] [Related]
16. Deprenyl and the progression of Parkinson's disease. Science; 1990 Jul; 249(4966):303-4. PubMed ID: 2115691 [No Abstract] [Full Text] [Related]
17. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Fuller RW; Hemrick-Luecke SK; Perry KW J Pharmacol Exp Ther; 1988 Nov; 247(2):531-5. PubMed ID: 3141609 [TBL] [Abstract][Full Text] [Related]
18. What is it that l-deprenyl (selegiline) might do? Tipton KF Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):781-96. PubMed ID: 7995021 [TBL] [Abstract][Full Text] [Related]
19. Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline. Lieberman A Neurology; 1992 Apr; 42(4 Suppl 4):37-40; discussion 41-8. PubMed ID: 1350073 [TBL] [Abstract][Full Text] [Related]
20. The neurotoxicity of MPTP and its relationship to the pathophysiology of Parkinson's disease. Sandyk R; Iacono RP Int J Neurosci; 1989 Jan; 44(1-2):165-7. PubMed ID: 2485822 [No Abstract] [Full Text] [Related] [Next] [New Search]